Mankind Pharma Signs Exclusive India Licensing Deal for US FDA-Approved Cancer Drug Ensartinib
Mumbai: Mankind Pharma has entered into an in-licensing agreement with China’s Betta Pharmaceuticals for the exclusive rights to develop, manufacture and commercialise the oncology drug Ensartinib in India.
Ensartinib is approved by the US Food and Drug Administration (FDA) and China’s National Medical Products Administration (NMPA). It is indicated for adults with anaplastic lymphoma kinase (ALK)-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an ALK inhibitor.
Under the agreement, Mankind Pharma will make an upfront payment to Betta Pharmaceuticals, along with potential development and sales milestone payments and royalties based on annual net sales in India.
Ensartinib is a targeted therapy that inhibits ALK, a protein associated with cancer growth in a subset of patients with non-small cell lung cancer.
The agreement is part of Mankind Pharma’s strategy to expand its oncology portfolio through partnerships with international pharmaceutical companies and strengthen its presence in specialised therapies.
Atish Majumdar, Senior President of Mankind Pharma, said the agreement would support the company’s expansion in oncology and its efforts to bring advanced treatment options to Indian patients.
Shizhe Ding, Chairman Assistant and Head of Business Development at Betta Pharmaceuticals, said the partnership would help expand Ensartinib’s reach and make the treatment available to a wider patient population.
The financial terms of the agreement include upfront, milestone and royalty payments, with the exclusive Indian licence subject to the agreement’s terms and conditions.

